{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:20:32Z","timestamp":1762867232230,"version":"3.37.3"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T00:00:00Z","timestamp":1504656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0183851","type":"journal-article","created":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T13:31:14Z","timestamp":1504704674000},"page":"e0183851","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis"],"prefix":"10.1371","volume":"12","author":[{"given":"Philip","family":"Vutien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-4989","authenticated-orcid":true,"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,9,6]]},"reference":[{"issue":"10049","key":"ref1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"JD Stanaway","year":"2016","journal-title":"Lancet"},{"key":"ref2","article-title":"Combating hepatitis B and C to reach elimination by 2030"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132056","article-title":"Correlates of initiation of treatment for chronic hepatitis C infection in United States Veterans, 2004\u20132009","volume":"10","author":"AV Gundlapalli","year":"2015","journal-title":"PLoS ONE"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/jvh.12080","article-title":"Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C","volume":"20","author":"ZM Younossi","year":"2013","journal-title":"J Viral Hepat"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/gut.2006.099150","article-title":"Rate and predictors of treatment prescription for hepatitis C","volume":"56","author":"AA Butt","year":"2007","journal-title":"Gut"},{"issue":"8","key":"ref6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1525-1497.2005.0161.x","article-title":"Barriers to the treatment of hepatitis C. Patient, provider, and system factors","volume":"20","author":"JA Morrill","year":"2005","journal-title":"J Gen Intern Med"},{"issue":"22","key":"ref7","doi-asserted-by":"crossref","first-page":"e3719","DOI":"10.1097\/MD.0000000000003719","article-title":"Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States","volume":"95","author":"P Vutien","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"EJ Gane","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"MS Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"D Moher","year":"2009","journal-title":"Journal of clinical epidemiology"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"P Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"ref12","unstructured":"Wells GA, Shea B, O&apos;Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2009. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp\" xlink:type=\"simple\">http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp<\/ext-link>."},{"key":"ref13","first-page":"1","article-title":"Closing the quality gap: revisiting the state of the science (vol. 3: quality improvement interventions to address health disparities)","volume":"208.3","author":"ML McPheeters","year":"2012","journal-title":"Evidence report\/technology assessment"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.cgh.2013.03.032","article-title":"A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir","volume":"11","author":"EY Chen","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1586\/17474124.2015.1095087","article-title":"Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C","volume":"9","author":"VV Chirikov","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/PPA.S30111","article-title":"Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection","volume":"6","author":"BT Clark","year":"2012","journal-title":"Patient Preference Adherence"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061568","article-title":"Nonresponse to Interferon-\u03b1 Based Treatment for Chronic Hepatitis C Infection Is Associated with Increased Hazard of Cirrhosis","volume":"8","author":"ML Cozen","year":"2013","journal-title":"PLoS ONE"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/liv.12536","article-title":"Barriers to HCV treatment in the era of triple therapy: a prospective multi-centred study in clinical practice","volume":"35","author":"J Crespo","year":"2015","journal-title":"Liver Int"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/00042737-200511000-00006","article-title":"Hepatitis C infection: eligibility for antiviral therapies","volume":"17","author":"J Delwaide","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MEG.0000000000000506","article-title":"Chronic hepatitis C: treat or wait? A prospective study on reasons for treatment or nontreatment in the era of first-generation protease inhibitors","volume":"28","author":"M Feillant","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1111\/j.1365-2893.2010.01370.x","article-title":"Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia","volume":"18","author":"J Grebely","year":"2011","journal-title":"J Viral Hepat"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jceh.2015.05.001","article-title":"Most Patients of Hepatitis C Virus Infection in India Present Late for Interferon-Based Antiviral Treatment: An Epidemiological Study of 777 Patients from a North Indian Tertiary Care Center","volume":"5","author":"V Gupta","year":"2015","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"ofv218","DOI":"10.1093\/ofid\/ofv218","article-title":"Clinical Care Pathways for Patients With Hepatitis C: Reducing Critical Barriers to Effective Treatment","volume":"3","author":"N Howes","year":"2016","journal-title":"Open forum infectious diseases"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"YC Hsu","year":"2015","journal-title":"Gut"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.dld.2013.08.139","article-title":"Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents","volume":"46","author":"JM Kittner","year":"2014","journal-title":"Dig Liver Dis"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1128\/AAC.04027-14","article-title":"Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease","volume":"59","author":"BK Kutala","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/jmv.24335","article-title":"Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea","volume":"88","author":"SS Lee","year":"2016","journal-title":"J MED VIROL"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","DOI":"10.3402\/ijch.v71i0.18445","article-title":"Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection","volume":"71","author":"SE Livingston","year":"2012","journal-title":"Int J Circumpolar Health"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2893.2005.00607.x","article-title":"Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C","volume":"12","author":"JS Markowitz","year":"2005","journal-title":"J Viral Hepat"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/jvh.12153","article-title":"Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland&apos;s Hepatitis C Action Plan","volume":"21","author":"SA McDonald","year":"2014","journal-title":"J Viral Hepat"},{"issue":"12","key":"ref31","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1872-034X.2007.00157.x","article-title":"Liver disease in hepatitis C virus carriers identified at blood donation and their outcomes with or without interferon treatment: Study on 1019 carriers followed for 5\u201310 years","volume":"37","author":"M Mizui","year":"2007","journal-title":"HEPATOL RES"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1155\/2007\/576765","article-title":"Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage","volume":"21","author":"R Moirand","year":"2007","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/cid\/cis815","article-title":"Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study","volume":"56","author":"AC Moorman","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"11","key":"ref34","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2893.2006.00763.x","article-title":"Treatment rates in patients with chronic hepatitis C after liver biopsy","volume":"13","author":"G Narasimhan","year":"2006","journal-title":"J Viral Hepat"},{"issue":"SI","key":"ref35","first-page":"1094A","article-title":"Low HCV treatment for chronic hepatitis C (CHC) patients in pre-protease inhibitor (PI) and post-PI\/pre-direct acting antiviral (DAA) eras compared to post-DAA era, especially in African Americans: analysis of a large real-world cohort of 7105 patients","volume":"62","author":"PT Nguyen","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"ref36","doi-asserted-by":"crossref","first-page":"S973","DOI":"10.1016\/S0016-5085(14)63539-3","article-title":"Comorbid conditions associated With decision-making regarding treating or not treating chronic hepatitis C in a large U.S. health maintenance organization","volume":"146","author":"LM Nyberg","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1665-2681(19)30786-0","article-title":"Reasons for HCV non-Treatment in underserved African Americans: Implications for treatment with new therapeutics","volume":"14","author":"S Schaeffer","year":"2015","journal-title":"Ann Hepatol"},{"issue":"4","key":"ref38","first-page":"250","article-title":"Population-based hepatitis C surveillance and treatment in a national managed care organization","volume":"10","author":"D Shatin","year":"2004","journal-title":"Am J Manag Care"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drugalcdep.2004.07.002","article-title":"The impact of injecting drug use status on hepatitis C-related referral and treatment","volume":"77","author":"MA Stoove","year":"2005","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"ref40","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.dld.2010.03.020","article-title":"Current practice of hepatitis C treatment in Southern Italy","volume":"42","author":"T Stroffolini","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"10","key":"ref41","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2893.2009.01227.x","article-title":"The impact of a managed care network on attendance, follow-up and treatment at a hepatitis C specialist centre","volume":"17","author":"JM Tait","year":"2010","journal-title":"J Viral Hepat"},{"issue":"4","key":"ref42","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/00365521.2013.863965","article-title":"Clinical outcomes in a cohort of anti-hepatitis C virus-positive patients with significant barriers to treatment referred to a Norwegian outpatient clinic","volume":"49","author":"KH Toresen","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-8-164","article-title":"Comparative study of patients with chronic hepatitis C virus infection due to genotypes 1 and 3 referred for treatment in southeast Brazil","volume":"8","author":"AG Vigani","year":"2008","journal-title":"BMC Infect Dis"},{"issue":"2","key":"ref44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.dld.2014.11.002","article-title":"Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon alpha plus ribavirin in chronic hepatitis C","volume":"47","author":"R Vukotic","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"12","key":"ref45","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1007\/s10620-010-1412-1","article-title":"Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital","volume":"55","author":"KK Yan","year":"2010","journal-title":"Dig Dis Sci"},{"key":"ref46","article-title":"Rate, delay and predictors of hepatitis C treatment in British Columbia","author":"HL Yau","year":"2015","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"5","key":"ref47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4088\/PCC.v10n0501","article-title":"10-year trends in the diagnosis and treatment of hepatitis C and concomitant mental health disorders: 1995 to 2005","volume":"10","author":"BP Yawn","year":"2008","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"13","key":"ref48","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1097\/MD.0000000000000690","article-title":"Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan","volume":"94","author":"ML Yu","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"ref49","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.21927","article-title":"Predictors of treatment in patients with chronic hepatitis C infection\u2014role of patient versus nonpatient factors","volume":"46","author":"F Kanwal","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"ref50","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1007\/s10620-006-9579-1","article-title":"Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time?","volume":"52","author":"OS Khokhar","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"3","key":"ref51","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/ajg.2010.430","article-title":"Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study","volume":"106","author":"JR Kramer","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"ref52","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.cgh.2016.03.040","article-title":"Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance","volume":"14","author":"V Lo Re 3rd","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"ref53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/cid\/civ220","article-title":"The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus","volume":"61","author":"DB Rein","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"ref54","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"MG Ghany","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"ref55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"55","year":"2011","journal-title":"J Hepatol"},{"issue":"2","key":"ref56","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12072-012-9342-y","article-title":"APASL consensus statements and management algorithms for hepatitis C virus infection","volume":"6","author":"M Omata","year":"2012","journal-title":"Hepatol Int"},{"key":"ref57","article-title":"Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents","author":"AM Moon","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"journal-title":"J Hepatol","article-title":"EASL Recommendations on Treatment of Hepatitis C 2016","year":"2016","key":"ref58"},{"issue":"5","key":"ref59","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"M Omata","year":"2016","journal-title":"Hepatol Int"},{"issue":"3","key":"ref60","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"ref61","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","author":"AP Thrift","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref62","article-title":"Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses","author":"K Zhou","year":"2016","journal-title":"Lancet Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0183851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T01:27:08Z","timestamp":1570066028000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0183851"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,6]]},"references-count":62,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0183851","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2017,9,6]]}}}